1
|
Doualle C, Gouju J, Nouari Y, Wery M, Guittonneau C, Codron P, Rousseau A, Saulnier P, Eyer J, Letournel F. Dedifferentiated cells obtained from glioblastoma cell lines are an easy and robust model for mesenchymal glioblastoma stem cells studies. Am J Cancer Res 2023; 13:1425-1442. [PMID: 37168329 PMCID: PMC10164819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Accepted: 02/12/2023] [Indexed: 05/13/2023] Open
Abstract
Glioblastoma is an aggressive brain tumor with a poor prognosis. Glioblastoma Stem Cells (GSC) are involved in glioblastoma resistance and relapse. Effective glioblastoma treatment must include GSC targeting strategy. Robust and well defined in vitroGSC models are required for new therapies evaluation. In this study, we extensively characterized 4 GSC models obtained by dedifferentiation of commercially available glioblastoma cell lines and compared them to 2 established patient derived GSC lines (Brain Tumor Initiating Cells). Dedifferentiated cells formed gliospheres, typical for GSC, with self-renewal ability. Gene expression and protein analysis revealed an increased expression of several stemness associated markers such as A2B5, integrin α6, Nestin, SOX2 and NANOG. Cells were oriented toward a mesenchymal GSC phenotype as shown by elevated levels of mesenchymal and EMT related markers (CD44, FN1, integrin α5). Dedifferentiated GSC were similar to BTIC in terms of size and heterogeneity. The characterization study also revealed that CXCR4 pathway was activated by dedifferentiation, emphasizing its role as a potential therapeutic target. The expression of resistance-associated markers and the phenotypic diversity of the 4 GSC models obtained by dedifferentiation make them relevant to challenge future GSC targeting therapies.
Collapse
Affiliation(s)
- Cécile Doualle
- Univ Angers, CHU Angers, Inserm, CNRS, MINT, SFR ICATF-49000 Angers, France
| | - Julien Gouju
- Univ Angers, CHU Angers, Inserm, CNRS, MINT, SFR ICATF-49000 Angers, France
- Département de Pathologie, CHU AngersF-49000 Angers, France
| | - Yousra Nouari
- Univ Angers, CHU Angers, Inserm, CNRS, MINT, SFR ICATF-49000 Angers, France
| | | | - Clélia Guittonneau
- Univ Angers, CHU Angers, Inserm, CNRS, MINT, SFR ICATF-49000 Angers, France
| | - Philippe Codron
- Département de Pathologie, CHU AngersF-49000 Angers, France
- Univ Angers, CHU Angers, Inserm, CNRS, MITOVASC, SFR ICATF-49000 Angers, France
| | - Audrey Rousseau
- Département de Pathologie, CHU AngersF-49000 Angers, France
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, SFR ICATF-49000 Angers, France
| | - Patrick Saulnier
- Univ Angers, CHU Angers, Inserm, CNRS, MINT, SFR ICATF-49000 Angers, France
| | - Joël Eyer
- Univ Angers, CHU Angers, Inserm, CNRS, MINT, SFR ICATF-49000 Angers, France
| | - Franck Letournel
- Univ Angers, CHU Angers, Inserm, CNRS, MINT, SFR ICATF-49000 Angers, France
- Département de Pathologie, CHU AngersF-49000 Angers, France
| |
Collapse
|
2
|
Darwiche W, Gomila C, Ouled-Haddou H, Naudot M, Doualle C, Morel P, Nguyen-Khac F, Garçon L, Marolleau JP, Ghamlouch H. Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia. J Exp Clin Cancer Res 2020; 39:228. [PMID: 33115525 PMCID: PMC7594454 DOI: 10.1186/s13046-020-01738-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Accepted: 10/14/2020] [Indexed: 02/17/2023]
Abstract
Background Novel, less toxic, cost-effective and safe therapeutic strategies are needed to improve treatment of chronic lymphocytic leukemia (CLL). Ascorbic acid (AA, vitamin C) has shown a potential anti-cancer therapeutic activity in several cancers. However, the anti-cancer effects of ascorbic acid on CLL B-cells have not been extensively studied. We aimed in this study to evaluate the in vitro therapeutic activity using clinically relevant conditions. Methods Primary CLL B-cells and two CLL cell lines were exposed to a dose that is clinically achievable by AA oral administration (250 μM), and cell death and potential mechanisms were assessed. The role of the protective CLL microenvironment was studied. Synergistic interaction between AA and CLL approved drugs (Ibrutinib, Idelalisib and Venetoclax) was also evaluated. Results Ascorbic acid is cytotoxic for CLL B-cells at low dose (250 μM) but spares healthy B-cells. Ascorbic-acid-induced cytotoxicity involved pro-oxidant damage through the generation of reactive oxygen species in the extracellular media and in CLL cells, and induced caspase-dependent apoptosis. We also found that AA treatment overcame the supportive survival effect provided by microenvironment including bone marrow mesenchymal stem cells, T-cell cues (CD40L + IL-4), cytokines and hypoxia. Our data suggest that resistance to AA could be mediated by the expression of the enzyme catalase in some CLL samples and by the glucose metabolite pyruvate. We also demonstrated that AA synergistically potentiates the cytotoxicity of targeted therapies used in or being developed for CLL. Conclusion These preclinical results point to AA as an adjuvant therapy with potential to further improve CLL treatments in combination with targeted therapies. Supplementary information Supplementary information accompanies this paper at 10.1186/s13046-020-01738-0.
Collapse
Affiliation(s)
- Walaa Darwiche
- EA 4666, HEMATIM, Université de Picardie Jules Verne, D408, 80054, Amiens Cedex, France. .,Service d'Hématologie Clinique, Centre Hospitalier Universitaire Amiens Picardie, D408, 80054, Amiens Cedex, France.
| | - Cathy Gomila
- EA 4666, HEMATIM, Université de Picardie Jules Verne, D408, 80054, Amiens Cedex, France
| | - Hakim Ouled-Haddou
- EA 4666, HEMATIM, Université de Picardie Jules Verne, D408, 80054, Amiens Cedex, France
| | - Marie Naudot
- EA 7516, CHIMERE, Université de Picardie Jules Verne, Amiens, France
| | - Cécile Doualle
- INSERM U1138, Centre de Recherche des Cordeliers, Sorbonne Université, Paris, France
| | - Pierre Morel
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire Amiens Picardie, D408, 80054, Amiens Cedex, France
| | - Florence Nguyen-Khac
- INSERM U1138, Centre de Recherche des Cordeliers, Sorbonne Université, Paris, France.,Hôpital Pitié-Salpêtrière, Sorbonne Université, APHP, Service d'Hématologie Biologique, Paris, France
| | - Loïc Garçon
- EA 4666, HEMATIM, Université de Picardie Jules Verne, D408, 80054, Amiens Cedex, France.,Service d'hématologie Biologique, Centre Hospitalier Universitaire Amiens Picardie, Amiens, France
| | - Jean-Pierre Marolleau
- EA 4666, HEMATIM, Université de Picardie Jules Verne, D408, 80054, Amiens Cedex, France. .,Service d'Hématologie Clinique, Centre Hospitalier Universitaire Amiens Picardie, D408, 80054, Amiens Cedex, France.
| | - Hussein Ghamlouch
- EA 4666, HEMATIM, Université de Picardie Jules Verne, D408, 80054, Amiens Cedex, France. .,INSERM U1170, équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif Cedex, France.
| |
Collapse
|